Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
rosuvastatin + ezetimibe + losartan + amlodipine
- Development stage
- Unknown
- Lead developer
- Hanmi Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HCP1306 + RLD2302 + RLD2102 is a fixed-dose combination (FDC) therapy developed by Hanmi Pharmaceutical for the management of hypertension and dyslipidemia. The combination consists of four active ingredients: rosuvastatin (an HMG-CoA reductase inhibitor), ezetimibe (a cholesterol absorption inhibitor), losartan (an angiotensin II receptor blocker), and amlodipine (a calcium channel blocker). HCP1306 specifically refers to the rosuvastatin/ezetimibe component, while RLD2302 and RLD2102 represent losartan and amlodipine, respectively. This quadruple combination, marketed in South Korea as Amosartan XQ, is designed to improve patient adherence by reducing the pill burden for patients who require simultaneous treatment for high blood pressure and high cholesterol.
- Brand names
- Amosartan XQ
- Other names
- HCP1306 + RLD2302 + RLD2102
02
Targets
LTCC (Voltage-gated calcium channel (L-type))NPC1L1 (Niemann-pick C1-Like 1 transporter)AGTR1 (Angiotensin II Type-1 receptor)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on rosuvastatin + ezetimibe + losartan + amlodipine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on rosuvastatin + ezetimibe + losartan + amlodipine.